Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB receptor family that is abnormally activated in many epithelial tumors. The aberrant activation of the EGFR leads to enhanced proliferation and other tumor-promoting activities, which provide a strong rationale to target this receptor family. There are two classes of anti-EGFR agents: monoclonal antibodies (MAbs) directed at the extracellular domain of the receptor and small molecule, adenosine triphosphate-competitive inhibitors of the receptor's tyrosine kinase. Anti-EGFR MAbs have shown antitumor activity in advanced colorectal carcinoma, squamous cell carcinomas of the head and neck, non-small-cell lung cancer (NSCLC) and…

• BC
  Breast Cancer Research Foundation

  Award: P30 CA68485
• VU
  Vanderbilt University

  Awards: P30 CA68485, CA68485
• NI
  National Institutes of Health

  Awards: CA68485, P50 CA98131, P30 CA68485, R01 grant